Loading company
BridgeBio Oncology Therapeutics, Inc.
BBOT · Nasdaq · ·
Next earnings: November 11, 2026
$3.92+2.9%Sep 29 close
- 1M
- -55.1%
- 6M
- -54.8%
- 1Y
- -66.1%
BBOT · Nasdaq · ·
Next earnings: November 11, 2026
$3.92+2.9%Sep 29 close
BridgeBio Oncology Therapeutics, Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$56.5M | -$28.4M | -98.54% |
| Free Cash Flow | -$44.4M | -$23.5M | -88.78% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
BridgeBio Oncology Therapeutics, Inc. has no earnings call transcript available.
“During the second quarter, we made meaningful progress in patient enrollment in our monotherapy and combination cohorts across each of our three clinical programs. Differentiated patient benefit in oncology is driven by optimal target coverage and the ability to combine with standard-of-care regimens. Therefore, we continue to focus heavily on advancing our combination development strategies,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from BridgeBio Oncology Therapeutics, Inc.’s Item 2.02 8-K filed August 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.